NEW YORK, December 21, 2016 /PRNewswire/ --
The Drug Manufacturers industry is focused on the research, distribution, and marketing of pharmaceutical drug products. Companies in this space typically have dividend yields that are higher than the Healthcare industry as a whole. This morning, Stock-Callers.com evaluates the following equities: Depomed Inc. (NASDAQ: DEPO), DURECT Corp. (NASDAQ: DRRX), United Therapeutics Corp. (NASDAQ: UTHR), and Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH). These stocks research reports can be downloaded now by simply registering for free at:
California headquartered Depomed Inc.'s stock finished Tuesday's session 1.48% lower at $17.94. A total volume of 1.92 million shares was traded, which was above their three months average volume of 1.75 million shares. The Company's shares are trading below their 200-day moving average by 8.90%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have a Relative Strength Index (RSI) of 33.18.
On November 07th, 2016, Depomed reported that Q3 2016 revenues were $111 million compared to $105 million for Q3 2015, representing an increase of 5%. The Company reported Q3 2016 net loss of ($12.9) million or ($0.21) per share, while on an adjusted basis, Depomed posted earnings of $20.9 million, or $0.28 per share. During Q3 2016, the Company received Favorable District Court ruling in Depomed's patent litigation against all three filers of Abbreviated New Drug Applications of the NUCYNTA franchise with expected market exclusivity until December 2025.
On December 12th, 2016, research firm Piper Jaffray downgraded the Company's stock rating from 'Neutral' to 'Underweight'. Your complete research report on DEPO can be retrieved for free at:
Shares in Cupertino, California headquartered DURECT Corp. ended at $1.32, jumping 4.76% from the last trading session. The stock recorded a trading volume of 508,429 shares. The Company's shares are trading 4.15% above their 50-day moving average. Moreover, shares of DURECT, which researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms, have an RSI of 53.06.
On October 31st, 2016, DURECT reported that total revenues were $3.7 million and net loss was $8.8 million for Q3 2016 compared to total revenues of $4.7 million and net loss of $6.5 million for Q3 2015. At September 30th, 2016, the Company had cash and investments of $29.0 million compared to cash and investments of $29.3 million at December 31st, 2015. At September 30th, 2016, DURECT had $19.8 million in long-term debt. DRRX free report is just a click away at:
Maryland headquartered United Therapeutics Corp.'s stock ended yesterday's session 1.49% higher at $145.38 with a total trading volume of 508,655 shares. The Company's shares have advanced 11.03% in the past month and 17.75% in the previous three months. The stock is trading 15.42% above its 50-day moving average and 22.40% above its 200-day moving average. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 68.07.
On October 27th, 2016, United Therapeutics reported that Q3 2016 revenues were $408.2 million, up 5.7% compared to revenue of $386.2 million for Q3 2015. The Company reported Q3 2016 net income of $161.8 million, reflecting a 65.2% decline compared to Q3 2015 net income of $464.4 million. In Q3 2016, United Therapeutics repurchased approximately 1.1 million shares of its common stock at an aggregate cost of $135.8 million.
On December 15th, 2016, research firm Oppenheimer initiated an 'Outperform' rating on the Company's stock. Sign up for your complimentary research report on UTHR at:
At the close on Tuesday, shares in California headquartered Amphastar Pharmaceuticals Inc. recorded a trading volume of 349,412 shares. The stock finished 1.92% higher at $20.69. The Company's shares have gained 45.40% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.33% and 24.07%, respectively. Furthermore, shares of Amphastar Pharma, which focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products, have an RSI of 55.19.
On November 08th, 2016, Amphastar reported net revenues of $64.2 million compared to $63.9 million for Q3 2015. The Company's cost of revenues was $36.6 million, or 57% of revenues, and $46.3 million, or 72% of revenues, for Q3 2016 and Q3 2015, respectively, representing a decrease of $9.7 million, or 21%. Amphastar reported net income of $3.9 million, or $0.08 per diluted share, for Q3 2016 compared to a net loss of $3.0 million, or $0.07 per diluted share, for Q3 2015. The Company's cash and cash equivalents as of September 30th, 2016, were $66.6 million. Register for free on Stock-Callers.com and download the latest research report on AMPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA